Example collocations logo

Pharmaceutical in sentence

484 examples of Pharmaceutical in a sentence

Since 2001-2002, the pharmaceutical sector has spent $1.1 trillion on research and development, but the 12 largest companies have received regulatory approval for only 139 new molecular compounds.
In particular, the pharmaceutical giant Novartis has found itself under the microscope in two countries.
NASA-related spinoffs, the Internet, GPS, breakthroughs in semiconductors, nuclear power, imaging technology, pharmaceutical innovations, and more: all are important and highly visible manifestations of industrial policy the American way.
Crowd-sourced competitions like DREAM Challenges and FoldIt show that important scientific findings can emerge from outside of universities and pharmaceutical companies.
Cheaper and more resilient electricity benefits everyone – from the sidewalk vendor to the most sophisticated pharmaceutical operation.
Given the risks involved, it is not surprising that pharmaceutical companies are very careful in their choice of investments in new drug or vaccine programs, selecting only those that promise financial gains sufficient to cover the costs of both successes and failures and provide a reasonable return on the required investment.
The easiest would be to spread the money around to scientists in academia, product-development partnerships, biotech firms, and larger pharmaceutical companies as opportunities arise.
An alternative would be to create a full-fledged, global, not-for-profit pharmaceutical company with a research budget equal to that of the world’s top five for-profit companies, and with the singular objective of creating a pipeline of products to address the challenge of infectious threats.
In India’s case, it is leveraging its clout as a major supplier of power and telecommunications equipment and active pharmaceutical ingredients, not to mention as a lender to financially troubled Indian firms, to limit the country’s options.
As CEO of a global pharmaceutical company, I’m proud of the work we have done to fight HIV/AIDS around the world.
The pharmaceutical industry has a responsibility to expand access to testing and treatment, and to help stop the spread of HIV once and for all.
For starters, pharmaceutical companies should do more to increase the availability of low-cost, generic medicines.
Margaret Thatcher was the first to realize that Britain’s specialization in services – not only finance, but also law, accountancy, media, architecture, pharmaceutical research and so on – makes membership in the EU single market critical.
Its advertising base is a little heavy on vitamin supplements, since pharmaceutical companies are extremely constrained in how they can advertise.
Likewise, such agreements should support fair access to pharmaceutical patents and to the data used to prove the safety of medical treatments.
Similarly, access to affordable medicines is something other countries desperately need; it is large pharmaceutical companies that are not entirely enthusiastic.
For example, when patients experience pain relief from placebos, the brain releases endogenous opioids and/or CB1 cannabinoids – the very same mechanisms that mediate pain relief derived from pharmaceutical treatments.
It seems only reasonable that the NDB should announce steps to support pharmaceutical research into new TB treatments and vaccines, particularly for drug-resistant strains, given that TB is especially prevalent in the BRICS.
India’s Patently Wise DecisionNEW YORK – The Indian Supreme Court’s refusal to uphold the patent on Gleevec, the blockbuster cancer drug developed by the Swiss pharmaceutical giant Novartis, is good news for many of those in India suffering from cancer.
But the Indian decision also means less money for the big multinational pharmaceutical companies.
Moreover, it is only a localized effort at rebalancing a global intellectual-property (IP) regime that is tilted heavily toward pharmaceutical interests at the expense of social welfare.
India represents only about 1-2% of the global pharmaceutical market.
But it has long been a flashpoint in battles over expansion of pharmaceutical companies’ global IP rights, owing to its dynamic generics industry and its willingness to challenge patent provisions both domestically and in foreign jurisdictions.
Much of this globally valuable capacity was built under a regime of weak – in fact, non-existent – protection for pharmaceutical patents.
As a result, there are now numerous overlapping protections for pharmaceutical companies that are very difficult for most developing countries to contest, and that often pit their global obligations against their domestic obligations to protect their citizens’ lives and health.
That is why the pharmaceutical industry, the US, and others have pushed since its inception for a wider and stronger set of standards through add-on agreements.
But the pharmaceutical industry, trying to consolidate its gains, has been pushing instead for an ever stronger and more imbalanced IP regime.
These bogus products have infiltrated pharmaceutical supply chains from Azerbaijan to Zambia, wrecking the most promising programs to control, manage, and eradicate deadly diseases.
We took action because cash-strapped national TB programs tend to be conservative about adopting new treatments, and because pharmaceutical manufacturers have little incentive to bring their drugs to market in poorer countries.
Some of the most profitable and powerful pharmaceutical companies in the world, AstraZeneca and Pfizer, have left that “market” behind.
Back